Novavax, Inc.
NASDAQ:NVAXBiotechnology
Healthcare
$7.72 -1.84%
-$0.18 today
- Market cap
- $1.27B
- Beta
- 2.41
- P/E (TTM)
- -17.3
- EPS (TTM)
- -$0.54
52W Low $6.13High $11.97
Volume 4.34M
Average 4.58M
Income Statement
Follow revenue through to earnings.
Revenue
$1.12B
FY 2025 · Annual
+64.7% YoYOperating Income
$563.27M
FY 2025 · Annual
Net Income
$440.30M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 197.58M | 1.6B | 556.38M | 682.16M | 1.12B |
| Cost of Revenue | 0 | 902.64M | 343.77M | 202.74M | 71.14M |
| Gross Profit | 197.58M | 696.31M | 212.61M | 479.42M | 1.05B |
| Gross Margin | 100.0% | 43.5% | 38.2% | 70.3% | 93.7% |
| Research & Development | 2.53B | 1.24B | 737.5M | 391.17M | 336.82M |
| Selling, General & Admin | 298.36M | 488.69M | 468.95M | 337.19M | 150.35M |
| Operating Expenses | 1.88B | 1.34B | 779.13M | 728.35M | 489.07M |
| Depreciation & Amortization | 12.66M | 29.05M | 41.23M | 48.5M | 27.61M |
| EBITDA | (1.68B) | (604.71M) | (487.39M) | (108.04M) | 492.33M |
| EBITDA Margin | -850.7% | -37.8% | -87.6% | -15.8% | 43.8% |
| Operating Income | (1.69B) | (644.74M) | (566.51M) | (248.93M) | 563.27M |
| Operating Margin | -853.6% | -40.3% | -101.8% | -36.5% | 50.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 21.13M | 19.88M | 14.42M | 20.08M | 22.55M |
| Other Income / Expenses | (27.96M) | (8.91M) | 23.48M | 72.32M | (121.1M) |
| Income Before Tax | (1.71B) | (653.65M) | (543.03M) | (176.62M) | 442.17M |
| Pre-Tax Margin | -867.8% | -40.9% | -97.6% | -25.9% | 39.4% |
| Income Tax Expense | 29.22M | 4.29M | 2.03M | 10.88M | 1.87M |
| Net Income | (1.74B) | (657.94M) | (545.06M) | (187.5M) | 440.3M |
| Net Margin | -882.5% | -41.1% | -98.0% | -27.5% | 39.2% |
| EPS (Basic) | (23.44) | (8.42) | (5.41) | (1.23) | 2.72 |
| EPS (Diluted) | (23.44) | (8.42) | (5.41) | (1.23) | 2.54 |
| 74.4M | 78.18M | 100.77M | 152.19M | 161.99M | |
| 74.4M | 78.18M | 100.77M | 152.19M | 173.1M |
NVAX Earnings Waterfall · TTM
NASDAQ:NVAX · Revenue to Net Income
Key Ratios
EPS$-0.60
Gross Margin81.1%
Net Margin-59.4%
P/E Ratio-4.7
P/S Ratio10.3
Analysis
$596.3M of revenue converted into -$87.8M of net income for the selected period. Gross margin is 81.1% and net margin is -59.4%, showing how much revenue survives after costs and taxes. EPS is $-0.60, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Oct 29, 2026 | |
| SC 13D/A | SC 13D/A filing | Oct 16, 2026 |
How much revenue does NVAX generate?
Novavax, Inc. (NVAX) reported $1.12B of revenue in fiscal 2025.
Is NVAX profitable?
Novavax, Inc. (NVAX) reported $440.30M of net income, with a net margin of 39.2%.
Continue the stock analysis
Jump to another research area for this company.